Trial Profile

Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raludotatug deruxtecan (Primary)
Indications Ovarian cancer; Renal cell carcinoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Daiichi Sankyo Inc

Most Recent Events

28 Jul 2025 Planned End Date changed from 30 Nov 2025 to 30 Jun 2026.
28 Jul 2025 Planned primary completion date changed from 21 Apr 2025 to 30 Apr 2026.
24 Dec 2024 Planned End Date changed from 30 Nov 2024 to 30 Nov 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com